Novocure's device shown to slow cancer progression in the brain in trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Novocure (NVCR) shares jump after trial meets primary endpoint
March 27, 2024 9:58 AM EDTShares of Novocure (NASDAQ: NVCR) jumped Wednesday after the company reported before the open that its phase 3 METIS clinical trial met its primary endpoint.
The company's lung cancer demonstrated the slowing in the progression of cancer to the brain in... More
